FFTY - ETF AI Analysis
Top Page
Innovator IBD 50 ETF (FFTY)
Rating:68Neutral
Price Target:―
Positive Factors
Strong Top Holdings Performance
Most of the largest positions have shown strong gains this year, which has helped support the ETF’s overall results.
Growth-Focused Sector Mix
Heavy exposure to technology, industrials, and health care gives investors targeted access to sectors that can benefit from innovation and economic growth.
Positive Year-to-Date Momentum
The fund’s performance so far this year has been positive, suggesting it has recently benefited from its stock selection.
Negative Factors
High Expense Ratio
The ETF charges relatively high annual fees, which can eat into long-term returns compared with lower-cost funds.
Concentrated Country Exposure
With almost all assets in U.S. stocks and only a small slice in Canada, the fund offers limited geographic diversification.
Short-Term Performance Volatility
The recent three-month performance has been weak despite a strong one-month rebound, indicating that returns can be quite up and down over shorter periods.
FFTY vs. SPDR S&P 500 ETF (SPY)
AUM94.23M
RegionNorth America
Expense Ratio0.80%
Beta1.39
IssuerCapForce
Inception DateApr 09, 2015
Dividend Yield1.15%
Asset ClassEquity
Index TrackedIBD 50 TR
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume42,471
30 Day Avg. Volume62,138
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
45.79Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering52
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FFTY Summary
The Innovator IBD 50 ETF (FFTY) is a fund that follows the IBD 50 Index, which picks 50 fast-growing U.S. and Canadian companies with strong sales and earnings trends. It mainly holds technology, industrial, and health care stocks, including names like Celestica and Rocket Lab USA. Investors might consider FFTY if they want a focused way to aim for higher growth than the overall market by owning a basket of leading growth stocks instead of picking individual names. However, because it concentrates on a small group of growth companies, its price can rise and fall more sharply than the broader market.
How much will it cost me?The Innovator IBD 50 ETF (FFTY) has an expense ratio of 0.8%, which means you’ll pay $8 per year for every $1,000 invested. This is higher than average because it’s actively managed, focusing on selecting top-performing growth stocks rather than passively tracking a broad index.
What would affect this ETF?The Innovator IBD 50 ETF (FFTY), with its focus on growth stocks and heavy exposure to technology and healthcare sectors, could benefit from advancements in innovation, favorable economic conditions, and increased investor interest in high-growth industries. However, it may face challenges from rising interest rates, regulatory changes, or economic slowdowns, which could negatively impact smaller-cap stocks and growth-focused companies. Its U.S.-centric portfolio also makes it sensitive to domestic market trends and policies.
FFTY Top 10 Holdings
FFTY is leaning hard into U.S. growth stories, with a clear tech and AI backbone. Chip names like Micron and AMD are doing the heavy lifting, riding the AI and data-center wave and giving the fund much of its recent spark. SiTime and Lumentum add to that tech-powered momentum, though their gains have been a bit more mixed. On the flip side, AnaptysBio looks more like a problem child, with weak fundamentals that can tug on returns. Overall, this is a concentrated, high-octane U.S. growth bet, not a sleepy index hugger.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| SiTime Corporation | 4.94% | $4.77M | $19.26B | 262.22% | 61 Neutral | |
| Micron | 4.08% | $3.94M | $1.04T | 927.95% | 79 Outperform | |
| Lumentum Holdings | 3.81% | $3.68M | $66.96B | 1082.84% | 61 Neutral | |
| Vertiv Holdings | 3.50% | $3.38M | $120.68B | 192.51% | 77 Outperform | |
| Comfort Systems | 3.46% | $3.34M | $65.31B | 282.29% | 80 Outperform | |
| AnaptysBio | 3.45% | $3.33M | $1.66B | 150.43% | 49 Neutral | |
| Bloom Energy | 3.40% | $3.28M | $82.49B | 1443.04% | 62 Neutral | |
| Argan | 3.21% | $3.10M | $9.46B | 217.18% | 73 Outperform | |
| Hut 8 | 3.21% | $3.10M | C$19.31B | 724.83% | 56 Neutral | |
| Advanced Micro Devices | 3.19% | $3.08M | $844.80B | 366.09% | 73 Outperform |
FFTY Technical Analysis
Positive
―
Price Trends
37.50
Positive
37.64
Positive
37.05
Positive
Market Momentum
0.76
Positive
57.03
Neutral
74.21
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FFTY, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 40.48, equal to the 50-day MA of 37.50, and equal to the 200-day MA of 37.05, indicating a bullish trend. The MACD of 0.76 indicates Positive momentum. The RSI at 57.03 is Neutral, neither overbought nor oversold. The STOCH value of 74.21 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FFTY.
FFTY Peer Comparison
Comparison Results
Performance Comparison
FFTY
Innovator IBD 50 ETF
40.72
10.29
33.82%
YALL
God Bless America ETF
―
―
―
BAMD
Brookstone Dividend Stock ETF
―
―
―
STNC
Stance Equity ESG Large Cap Core ETF
―
―
―
SOVF
Sovereign's Capital Flourish Fund
―
―
―
ABLD
Abacus FCF Real Assets Leaders ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents